Want to see JP:4577 full AI Analyst Report?
Top Page
Daito Pharmaceutical Co., Ltd.
(4577)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥1,430.00
▲(5.46% Upside)
Action:Reiterated
Date:10/11/26
The score is primarily driven by mixed financial performance: strong balance-sheet stability and improving (now positive) free cash flow are offset by a sharp TTM revenue contraction and still-below-peak margins. Valuation is supportive (moderate P/E and ~3% yield), while technical indicators are broadly neutral, indicating no strong momentum tailwind.
Positive Factors
Conservative balance sheet
Low leverage and a substantial equity buffer reduce financial strain during demand or pricing volatility. This gives Daito greater resilience, preserves borrowing capacity, and supports continued investment or other capital allocation choices over the next several quarters.
Negative Factors
Sharp revenue contraction
A contraction of this magnitude is a material challenge to the company’s growth profile and future operating leverage. Prolonged top-line weakness could reduce scale benefits, constrain investment capacity, and make it harder for earnings to return to prior peak levels.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a substantial equity buffer reduce financial strain during demand or pricing volatility. This gives Daito greater resilience, preserves borrowing capacity, and supports continued investment or other capital allocation choices over the next several quarters.
Read all positive factors
Daito Pharmaceutical Co., Ltd. (4577) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥39.32B
Dividend Yield2.98%
Average Volume (3M)65.20K
Price to Earnings (P/E)12.3
Beta (1Y)0.24
Revenue Growth-2.83%
EPS Growth65.69%
CountryJP
Employees1,085
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)107.46
Shares Outstanding28,854,880
10 Day Avg. Volume62,140
30 Day Avg. Volume65,199
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.65
Price to Sales (P/S)0.68
P/FCF Ratio6.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)88.7
Revenue Forecast (FY)¥54.00B
Daito Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both pr...
Daito Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
56
Neutral
| Breakdown | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.65B | 50.64B | 46.90B | 45.10B | 43.46B |
| Gross Profit | 9.90B | 8.47B | 9.67B | 10.15B | 11.31B |
| EBITDA | 8.02B | 7.41B | 7.92B | 8.96B | 10.04B |
| Net Income | 3.16B | 1.91B | 3.29B | 3.60B | 4.67B |
Balance Sheet | |||||
| Total Assets | 73.29B | 78.00B | 77.71B | 70.55B | 64.94B |
| Cash, Cash Equivalents and Short-Term Investments | 954.00M | 2.21B | 2.73B | 3.61B | 4.38B |
| Total Debt | 9.29B | 11.88B | 8.72B | 4.89B | 3.44B |
| Total Liabilities | 20.35B | 25.93B | 25.44B | 19.58B | 17.26B |
| Stockholders Equity | 52.89B | 52.00B | 52.07B | 50.67B | 47.31B |
Cash Flow | |||||
| Free Cash Flow | 5.53B | -957.00M | -1.04B | -1.35B | -257.00M |
| Operating Cash Flow | 9.38B | 5.90B | 5.18B | 4.16B | 4.37B |
| Investing Cash Flow | -4.39B | -7.37B | -5.93B | -5.57B | -4.33B |
| Financing Cash Flow | -6.29B | 1.00B | -183.00M | 616.00M | 921.00M |
Daito Pharmaceutical Co., Ltd. Technical Analysis
Positive
1356.00
Price Trends
1308.08
Positive
1267.44
Positive
1309.91
Positive
Market Momentum
5.82
Negative
63.01
Neutral
56.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4577, the sentiment is Positive. The current price of 1356 is above the 20-day moving average (MA) of 1312.85, above the 50-day MA of 1308.08, and above the 200-day MA of 1309.91, indicating a bullish trend. The MACD of 5.82 indicates Negative momentum. The RSI at 63.01 is Neutral, neither overbought nor oversold. The STOCH value of 56.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4577.
Daito Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥107.87B | 12.13 | 6.64% | 2.62% | 14.72% | 52.55% | |
67 Neutral | ¥39.32B | 12.34 | ― | 2.98% | -2.83% | 65.69% | |
66 Neutral | ¥54.29B | 12.19 | ― | 3.22% | ― | -7.20% | |
60 Neutral | ¥47.72B | 15.42 | 6.04% | 2.19% | 20.36% | -5.53% | |
52 Neutral | ¥56.38B | 28.41 | ― | 2.27% | -4.71% | -78.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥5.58B | -44.90 | ― | 3.24% | 0.60% | -131.22% |
* Healthcare Sector Average
JP:4577
Daito Pharmaceutical Co., Ltd.
1,344.00
185.68
16.03%
JP:4554
Fuji Pharma Co., Ltd.
1,835.00
262.73
16.71%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,145.00
162.51
5.45%
JP:4539
Nippon Chemiphar Co., Ltd.
1,542.00
30.11
1.99%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,074.00
-312.19
-22.52%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,023.00
-33.07
-1.61%
Daito Pharmaceutical Co., Ltd. Corporate Events
Daito and Partners Launch JV to Acquire KYORIN Generic Drug Unit
Sep 30, 2026
Daito Pharmaceutical has joined with Meiji Seika Pharma and the Development Bank of Japan to form Pharmatech Co-creation Platform, Inc., a new joint venture that will acquire KYORIN Pharmaceutical’s consolidated subsidiary KYORIN Rimedio, ex...
Daito Pharmaceutical Completes ¥605 Million Share Buyback to Boost Capital Efficiency
Jul 13, 2026
Daito Pharmaceutical has completed a share buyback under its Medium-Term Management Plan as part of efforts to enhance shareholder returns and improve capital efficiency. The company acquired 484,000 shares, equivalent to about 1.7% of its outstan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.